Kiromic BioPharma (NASDAQ:KRBP) Stock Price Down 3.5% – Time to Sell?

Shares of Kiromic BioPharma, Inc. (NASDAQ:KRBP) dropped 3.5% during mid-day trading on Friday . The stock traded as low as $0.91 and last traded at $1.09. Approximately 865 shares traded hands during mid-day trading, a decline of 82% from the average daily volume of 4,899 shares. The stock had previously closed at $1.13.

Kiromic BioPharma Trading Down 3.5 %

The company has a market capitalization of $1.72 million, a price-to-earnings ratio of -0.17 and a beta of 1.97. The stock’s 50 day moving average price is $1.16 and its 200 day moving average price is $1.91.

Kiromic BioPharma Company Profile

Kiromic BioPharma, Inc, a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1.